These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 11980628)

  • 1. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
    Bruns C; Lewis I; Briner U; Meno-Tetang G; Weckbecker G
    Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.
    Weckbecker G; Briner U; Lewis I; Bruns C
    Endocrinology; 2002 Oct; 143(10):4123-30. PubMed ID: 12239124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
    Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis.
    Park S; Kamegai J; Johnson TA; Frohman LA; Kineman RD
    Endocrinology; 2000 Oct; 141(10):3556-63. PubMed ID: 11014208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin.
    Afargan M; Janson ET; Gelerman G; Rosenfeld R; Ziv O; Karpov O; Wolf A; Bracha M; Shohat D; Liapakis G; Gilon C; Hoffman A; Stephensky D; Oberg K
    Endocrinology; 2001 Jan; 142(1):477-86. PubMed ID: 11145612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug design at peptide receptors: somatostatin receptor ligands.
    Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
    J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous and heterologous in vitro regulation of pig pituitary somatostatin receptor subtypes, sst1, sst2 and sst5 mRNA.
    Luque RM; Park S; Peng XD; Delgado E; Gracia-Navarro F; Kineman RD; Malagón MM; Castaño JP
    J Mol Endocrinol; 2004 Apr; 32(2):437-48. PubMed ID: 15072550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
    van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.
    Lewis I; Bauer W; Albert R; Chandramouli N; Pless J; Weckbecker G; Bruns C
    J Med Chem; 2003 Jun; 46(12):2334-44. PubMed ID: 12773038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
    Schmid HA; Silva AP
    J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
    Murray RD; Kim K; Ren SG; Lewis I; Weckbecker G; Bruns C; Melmed S
    J Clin Endocrinol Metab; 2004 Jun; 89(6):3027-32. PubMed ID: 15181094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
    Ruan W; Fahlbusch F; Clemmons DR; Monaco ME; Walden PD; Silva AP; Schmid HA; Kleinberg DL
    Mol Endocrinol; 2006 Feb; 20(2):426-36. PubMed ID: 16223973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.
    Murray RD; Kim K; Ren SG; Chelly M; Umehara Y; Melmed S
    J Clin Invest; 2004 Aug; 114(3):349-56. PubMed ID: 15286801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.
    Djordjijevic D; Zhang J; Priam M; Viollet C; Gourdji D; Kordon C; Epelbaum J
    Endocrinology; 1998 May; 139(5):2272-7. PubMed ID: 9564833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
    Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies.
    van Hoek M; Hofland LJ; de Rijke YB; van Nederveen FH; de Krijger RR; van Koetsveld PM; Lamberts SW; van der Lely AJ; de Herder WW; Feelders RA
    J Clin Endocrinol Metab; 2009 Feb; 94(2):428-33. PubMed ID: 19017754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
    J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity.
    Liu S; Crider AM; Tang C; Ho B; Ankersen M; Stidsen CE
    Curr Pharm Des; 1999 Apr; 5(4):255-63. PubMed ID: 10101224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding properties of somatostatin receptor subtypes.
    Bruns C; Raulf F; Hoyer D; Schloos J; Lübbert H; Weckbecker G
    Metabolism; 1996 Aug; 45(8 Suppl 1):17-20. PubMed ID: 8769372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.